The inhibitors, 50 μmol/l PDTC, 100 nmol/l bortezomib and 12.5 mg/l SN50, suppressed the NF-κB expression of the tumor cells themselves, which was stimulated by chemotherapy (P<0.05). The gene discussed is NFKB1; the disease is neoplasm.